Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
10 MILLION MORE bids than asks!
You would have been correct this past Thursday or Friday, but today is a different story. There are volume buys at the ask! 10 or 20 million will not be difficult to break in this current environment.
Glad I'm long here!
Since you already spoke with him, I suggest you call him back and ask him to make public what he told you personally.
Breaking through .0021 and all of the resistance there could be extremely significant!
More than 20 Million on the bid...
I disagree about the "dumping."
Yesterday, a buyer of about 40 million shares came in. And, some shareholders who thought it was worthless were happy to get anything for it. Paradigm could have gone bankrupt years ago, but management chose to keep it alive. If additional capital is raised, why would management file for bankruptcy now?
CORRECTION: From Page 6 of the Quarterly Report For the Quarter Ended June 30, 2013 (http://paradigm-medical.com/Library/Quarterly_Report_062013.pdf):
"The Company is actively seeking additional capital and financing but there can be no assurance that it will obtain such additional capital and financing. Without additional capital and financing, the Company will be unable to resume its business operations."
Perhaps someone (or more than one someone!) thinks the Company IS CLOSE TO OBTAINING ADDITIONAL CAPITAL AND FINANCING???
For all of our sake, let's hope that he, she or they are correct!
From Page 6 of the Quarterly Report For the Quarter Ended June 30, 2013:
insert-text-here
"The Company is actively seeking additional capital and financing but there can be no assurance that it will obtain such additional capital and financing. Without additional capital and financing, the Company will be unable to resume its business operations."
Perhaps someone (or more than one someone!) things the Company IS CLOSE TO OBTAINING ADDITIONAL CAPITAL AND FINANCING???
For all of our sake, let's hope that he, she or they are correct!
Now .0032 - .0033 on ETrade Level II!
PR Newswire RiceBran Technologies 2/5/14 (Yesterday) 8:15 AM
finance.yahoo.com/news/ricebran-technologies-complete-phase-1-131500420.html
RiceBran Technologies to Complete Phase 1 Plant Expansion at Irgovel Facility in the First Quarter
Sees 50% Increase in Capacity Boosting Sales and Margin in Second Half of 2014
PR Newswire RiceBran Technologies
February 5, 2014 8:15 AM
SCOTTSDALE, Arizona, February 5, 2014 /PRNewswire/ --
RiceBran Technologies (RIBT) and (RIBTW) (the "Company" or "RBT"), a global leader in the production and marketing of value added products derived from rice bran, today provided an update on the plant expansion projects underway at its Pelotas, Brazil-based rice bran oil bio-refining subsidiary Irgovel - Industria Riograndense de Oleos Vegetais Ltda.
As previously announced, RiceBran Technologies intended to direct a significant portion of the proceeds of its recent equity raise to increase capital at Irgovel. That additional funding is being used to complete the final phase of a series of projects aimed at updating and expanding all aspects of its rice bran bio-refining facility including an increase in raw rice bran (RRB) processing capacity at Irgovel from 6,000 metric tons per month to more than 9,000 metric tons per month. The series of related expansion and plant upgrade projects described by management as the Phase 1 Projects was necessitated by growing global demand for rice bran oil due to its known health benefits and attractive functional characteristics such as a high smoke point in frying.
The final and most important part of the Phase 1 Projects is the upgrading and expansion of the crude oil extraction plant, responsible for extracting crude rice bran oil from the RRB prior to refining, along with installation of a state-of-the-art desolventizer/toaster (DT), condensors and related equipment. Irgovel halted operations on January 16, 2014 to complete this final phase and expects to be fully operational with the increased capacity in place before the end March. Orders for increased rice bran oil production expected from the additional capacity have already begun to be placed. Management expects strong demand for its rice bran oil to continue going forward.
W. John Short, CEO & President of RBT and Chairman of the Management Committee at Irgovel commented "We expect to complete this important expansion project by the end of the first quarter. In the second quarter, we plan to restart the plant and debug the new equipment as we ramp up production to hit planned capacity of more than 9,000 metric tons per month in the second half of 2014. Based on new orders already placed for our increased rice bran oil capacity and inquiries from both current and new customers, we are confident that demand for our degummed, dewaxed, neutralized and fully refined rice bran oil products will remain strong for the foreseeable future."
Short continued, "While the expansion will result in a short term reduction in shipments at Irgovel, we believe the significant economic benefits of this expansion in the second half of 2014 will result in improved overall sales and margin performance at Irgovel compared to 2013. We anticipate the full effect of the expansion will lead to significant improvements in financial performance in 2015 and beyond."
In addition to increasing RRB processing capacity by more than 50%, the project phases completed over the past 15 months include: upgrading the on-site water treatment plant; installation of a new, more efficient boiler that burns rice hulls to provide steam needed for operations; drilling of three wells on site to provide the necessary water sources for boiler operation; installation and upgrading of electrical systems including a new power substation; construction of new buildings and installation of a new system for receiving and storing raw rice bran; installation of new technology for cleaning and extruding raw rice bran expected to increase quality and productivity of oil extraction; construction of a new, state-of-the-art animal nutrition plant that allows both wet and dry blending of compounded animal feed aimed at domestic and international markets for dairy and beef cattle, swine, sheep and equine markets among others; installation of rice lecithin extraction equipment; and the upgrade and 50% capacity expansion of the free fatty acid distilling plant.
Forward-Looking Statements
This release contains forward-looking statements, including, but not limited to, statements about RiceBran Technologies' expectations regarding completion of plant expansion and future sales and margin expectations for its Brazil Segment and improved prospects in 2014 and beyond. These statements are made based upon current expectations that are subject to known and unknown risks and uncertainties. RiceBran Technologies does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in RiceBran Technologies' filings with the Securities and Exchange Commission, including its most recent periodic reports.
About RiceBran Technologies
RiceBran Technologies is a human food ingredient and animal nutrition company focused on the procurement, bio-refining and marketing of numerous products derived from rice bran. Rice Bran Technologies has proprietary and patented intellectual property that allows us to convert rice bran, one of the world's most underutilized food sources, into a number of highly nutritious human food ingredient and animal nutrition products. Our target markets are human food ingredients and animal nutrition manufacturers and retailers, as well as natural food, functional food and nutraceutical supplement manufacturers and retailers, both domestically and internationally. More information can be found in our filings with the SEC and by visiting our website at http://www.ricebrantech.com .
Investor Contact:
Ascendant Partners, LLC
Fred Sommer
+1(732)410-9810
fred@ascendantpartnersllc.com
RIBT SHOULD THRIVE...
until and unless there is a major transformation within the human population, and the taste of brown rice becomes preferred over that of white. It certainly seems realistic to think that any one who has bought into Rice Bran Technologies after the recent capitalization restructuring - and who remains in it - will reap many rewards from the nutritional benefits and economic advantages of rice bran. I welcome any contrary opinion.
Good buying, and the bid is getting stronger. The bid and asked shown by the market makers is currently 82,496,000 x 43,521,000. This positive ratio could not even have been contemplated a couple of months ago!
Make that 66 purchases of 999,999 sh at .0002 and 1 purchase of 7,000,000 sh. at .0002. Total volume is 73 million.
Make that 25 purchases (the last 7 split up totaling 999,999 each) at .0002 in the last 22 minutes.
In the past 10 minutes, someone has bought 999,999 sh. 10 times, and counting...
12,999,999 purchased at .0002!!!!
More than 66 million shares on the bid this morning!!!
Correction: This link should work.
Here is Retimax (Paramax) info from Costruzioni Strumenti Oftalmici's (CSO) website:
http://www.csoitalia.it/ELETTROFISIOLOGIA.html
RETIMAX
A tool that combines standard electrophysiology with more advanced testing for functional diagnosis of early glaucoma and age-related maculopathy. Thanks to the advanced technology used RETIMAX to detect malfunctions within 20-40 degrees of retinal structure in the area, in a very early stage before they can cause faults in the peripheral visual field. The interpretation of the results is easy and
fast thanks to the comparison of the test with an internal archive normalized.
RETIMAX
Advanced Plus
RETIMAX Advanced PLUS is the new device for the Test elettrofunzionli multifocal ERG, PERG, VEP, and adds new and important changes to the test electrofunctional Standard. These tests are very useful and very reliable for the diagnosis of retinal diseases;
Glaucoma, Macular degeneration (ARMD), Retinitis Pigmentosa and scotoma of a few millimeters can be located and highlighted. The extension of the retinal damage can be accurately quantified market, especially in the early stage of evolution of the pathology. With the new algorithm "Total Length Real Time Binary M-Sequence" (Patent Pending)
RETIMAX Advanced Plus provides the ability to run tests quickly and very accurately. The obtained results are easy to interpret thanks to the statistical database age-related.
Here is Retimax (Paramax) info from Costruzioni Strumenti Oftalmici's (CSO) website:
http://www.csoitalia.it/ELETTROFISIOLOGIA.html[color=red][/color]
RETIMAX
A tool that combines standard electrophysiology with more advanced testing for functional diagnosis of early glaucoma and age-related maculopathy. Thanks to the advanced technology used RETIMAX to detect malfunctions within 20-40 degrees of retinal structure in the area, in a very early stage before they can cause faults in the peripheral visual field. The interpretation of the results is easy and
fast thanks to the comparison of the test with an internal archive normalized.
RETIMAX
Advanced Plus
RETIMAX Advanced PLUS is the new device for the Test elettrofunzionli multifocal ERG, PERG, VEP, and adds new and important changes to the test electrofunctional Standard. These tests are very useful and very reliable for the diagnosis of retinal diseases;
Glaucoma, Macular degeneration (ARMD), Retinitis Pigmentosa and scotoma of a few millimeters can be located and highlighted. The extension of the retinal damage can be accurately quantified market, especially in the early stage of evolution of the pathology. With the new algorithm "Total Length Real Time Binary M-Sequence" (Patent Pending)
RETIMAX Advanced Plus provides the ability to run tests quickly and very accurately. The obtained results are easy to interpret thanks to the statistical database age-related.
10,000,000 at .0002!!!
A hunch, or something much more???
Thank you for that thorough, scholarly analysis.
I bought more this morning, and not for just a 100% return! I believe what is stated in the latest press release!!
I took advantage of this tremendous opportunity this morning. I believe in the CEO and expect an FDA decision on the Paramax in the near future. I also think that those who have patience and recognize buying opportunities will flourish.
Except, I don't feel burned. I was able to buy more stock (even today) at significantly lower prices. What an opportunity this is, in my opinion!
I disagree. Mr. Davis has assured investors that the application and additional requested information had been sent to the FDA.
The day after it comes out (if positive), there will be many disappointed "non-believers."
I think it has dropped this low because of two main reasons. 1) There is a risk of further significant dilution. 2) Investors have lost belief in the company and its prospects, and they have lost patience. If and when the FDA decision does come out favorably, there will be numerous new investors with considerable confidence in PDMID, who will more than fill the void.
LOL - PDMID is not trading where it is for nothing. Of course there are serious concerns about the company. However, there is also significant potential; especially, receiving FDA approval for the Paramax. I think Mr. Davis is genuinely interested in making Paradigm profitable, and is taking essential steps to make it happen.
Again, I have taken the risk, and, obviously, think that I will be rewarded for having done so. It is readily apparently that I have more belief in Mr. Davis and Paradigm Medical.
Mach,
The investors who have panicked have offered a fantastic buying opportunity to those with patience, vision and trust in the process. If you have truly acted on your words, I think you could be extremely disappointed in the very near future.
RE-SENT from yesterday: There is more for Paradigm besides FDA approval.
Please see Post #17441 from October 9, 2009. Here is the direct link: insert-text-here In that post, it is written: "3) CPT-11 code for reimbursement (“ The Blood Flow Analyzer™ is expected to have a new CPT reimbursement code for Medicare insurance providers issued before the end of 2009”)." Perhaps a change in the coding is imminent??? If it does receive the new coding, it could play a key role in bringing the company to profitability.
There is more for Paradigm besides FDA approval.
Please see Post #17441 from October 9, 2009. Here is the direct link: insert-text-here In that post, it is written: "3) CPT-11 code for reimbursement (“ The Blood Flow Analyzer™ is expected to have a new CPT reimbursement code for Medicare insurance providers issued before the end of 2009”)." Perhaps a change in the coding is imminent??? If it does receive the new coding, it could play a key role in bringing the company to profitability.
I have more than my fingers crossed! I am all in!!
It is very interesting watching the sentiment of the message board go from extreme optimism to ultimate doom within 2 days, when nothing at all has happened to Paradigm Medical.
Contrary to what some have written, I sincerely doubt that Mr. Davis is an evil man, or that he has lied about the future plans of PDMID, including the upcoming FDA decision for the Paramax.
To me, the sell-off represents an unbelievable buying opportunity!
How quickly people forget! Yesterday, PDMID traded as low as .23 cents, that's point 23 cents, before rising to 7.3 cents. Just have a little patience!!!
How would FDA approval effect Paradigm's stock price
If and when PDMI receives FDA 510K approval for the Paramax (Retimax), it is almost certain that there will be more than a few investors purchasing Paradigm stock who had never heard of the company the day before the announcement of the FDA decision. Since it's all about supply & demand, it only figures that there would be upward pressure on the stock price. And, I am confident that the application for FDA approval has been made and is under consideration.
Kittie, Paradigm did receive FDA approval on 2/6/07 to market a new generation of Ultrasound devices: WIRELESS NEWS-February 7, 2007-Paradigm Medical Gets FDA Approval for New-Generation Ultrasound Devices:
www.allbusiness.com/legal/health-care-law-drug-medical-devices-approval/8391780-1.html.
Watch the Volume & PPS After the Announcement
Why PDMI Will Rise Significantly After FDA Approval
Upon finding out that PDMI has received FDA approval for the Paramax, many investors who had not heard of Paradigm Medical the day before, will be buying the company's stock at less than one penny per share. It is that simple!
Exactly, Color OM, it's all about the FDA![color=red][/color]
Key to PR: FDA's Continued Consideration of Paramax
Today's press release, combined with Mr. Davis's statement in the August 10, 2010 update on Paradigm's website - Paradigm Medical Quarterly Update - "...but it appears there are no major obstacles standing in the way of receiving 510(k) approval from the FDA in order to begin selling the Paramax™ in the United States", provides me with much optimism regarding PDMI.